Exact Sciences Corp (EXK.BE)
| Previous close | 55.12 |
| Open | 55.74 |
| Bid | 54.53 x N/A |
| Ask | 55.09 x N/A |
| Day's range | 54.79 - 55.74 |
| 52-week range | 51.34 - 94.80 |
| Volume | |
| Avg. volume | 5 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Exact Sciences Corporation's (NASDAQ:EXAS) Profit Outlook
With the business potentially at an important milestone, we thought we'd take a closer look at Exact Sciences...
Business WireExact Sciences Names Aaron Bloomer as New Chief Financial Officer
MADISON, Wis., April 15, 2024--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024.
Business WireExact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes
MADISON, Wis., April 11, 2024--Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on April 10, 2024 it entered into privately negotiated exchange and purchase agreements (the "Agreements") with certain holders of the Company’s 0.3750% Convertible Senior Notes due 2028 (the "Existing Notes"). Pursuant to the Agreements, the Company has agreed to issue to the holders $620.7 million aggregate principal amount of a n
